Corporate / M&A

Capital Markets

Sophia Genetics_bw

On July 23, 2021, SOPHiA GENETICS SA listed its shares on the Nasdaq Stock Market (ticker: SOPH). SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. Through its IPO, at USD 18.00 per share, SOPHiA GENETICS raises gross proceeds of USD 234 m.
Homburger acted as issuer&#8217;s Swiss counsel in this transaction. The Homburger team is led by partners Dieter Gericke and Daniel Häusermann (both Corporate / M&amp;A, Capital Markets) and includes partner Reto Heuberger (Tax), associates Estelle Piccard (Corporate / M&amp;A, Capital Markets), Ivan Marijanovic (Employment and Executive Compensation), Gabriel Kasper (Data Protection) and Philippe Weber (Tax) as well as junior associates Alessandra Dumitru and Ferdinand Berthold (both Corporate / M&amp;A, Capital Markets).

Homburger advises SOPHiA GENETICS in its NASDAQ IPO 

Archimed

On June 24, 2021, private equity healthcare fund ArchiMed announced the acquisition of Stragen Pharma from its founder and several shareholders. Based near Geneva, Switzerland and founded in 1990, Stragen is a developer of hard-to-make, complex generic drugs for the treatment of patients with life-threatening conditions that require comprehensive care and monitoring, usually in intensive care units. Stragen sales of some EUR 70 m in 2020 are growing at a double-digit annual pace. Stragen’s 40 different products are sold in over 60 countries around the world, with a strong European focus.
Homburger acted as Swiss legal counsel to ArchiMed. The Homburger team was led by partner Frank Gerhard, and comprised lead associate Sarah Chevalley, associate Léonard Aeschlimann Perales and junior associate Alessandra Dumitru (all Corporate / M&amp;A), as well as counsel Peter Müller (Tax).

Homburger advised private equity fund ArchiMed on the acquisition of Stragen Pharma

On June 22, 2021, the founder and owner of Groupe 3R (Réseau Radiologique Romand SA) announced jointly with Naxicap Partners the sale of Groupe 3R to private equity firm Naxicap Partners. Groupe 3R is an independent Swiss radiology network with more than 160 health professionals in the French-speaking part of Switzerland.
Homburger advised the Seller on this matter throughout the entire process. The Homburger team was led by partner Frank Gerhard, and comprised lead associate Guy Deillon, associates Sarah Chevalley, Olivier Bühlmann, Léonard Aeschlimann Perales and junior associate Alessandra Dumitru (all Corporate / M&amp;A), partner Stefan Oesterhelt, associates Laetitia Fracheboud and Raphaël Fellay (all Tax).

Alessandra
Dumitru

Homburger advises SOPHiA GENETICS in its NASDAQ IPO

Homburger advised private equity fund ArchiMed on the acquisition of Stragen Pharma

Homburger advised the Seller on the sale of a majority stake in Groupe 3R to private equity firm Naxicap Partners

Join the Team

Alessandra Dumitru

Career

Languages

Bar Registration

Teams